The WTX Tumor Suppressor Enhances p53 Acetylation by CBP/p300

Molecular Cell

Volumn 45, Issue 5, 2012, Pages 587-597

  Kim, Woo Jae ^a   Rivera, Miguel N ^a   Coffman, Erik J ^a   Haber, Daniel A ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

E1B PROTEIN; HISTONE ACETYLTRANSFERASE PCAF; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; WTX PROTEIN;

ACETYLATION; ADENOVIRUS; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CONTROLLED STUDY; CYTOPLASM; DNA BINDING MOTIF; GENE EXPRESSION; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; TUMOR SUPPRESSOR GENE;

ACETYLATION; ADAPTOR PROTEINS, SIGNAL TRANSDUCING; HEK293 CELLS; HUMANS; P300-CBP TRANSCRIPTION FACTORS; PROTEIN STABILITY; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

ADENOVIRIDAE;

EID: 84858047563     PISSN: 10972765     EISSN: 10974164     Source Type: Journal    
DOI: 10.1016/j.molcel.2011.12.025     Document Type: Article

References (55)

1. Bardeesy N., Falkoff D., Petruzzi M.J., Nowak N., Zabel B., Adam M., Aguiar M.C., Grundy P., Shows T., Pelletier J. Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations. Nat. Genet. 1994, 7:91-97.
2. Bardeesy N., Beckwith J.B., Pelletier J. Clonal expansion and attenuated apoptosis in Wilms' tumors are associated with p53 gene mutations. Cancer Res. 1995, 55:215-219.
3. Berk A.J. Recent lessons in gene expression, cell cycle control, and cell biology from adenovirus. Oncogene 2005, 24:7673-7685.
4. Donehower L.A., Harvey M., Slagle B.L., McArthur M.J., Montgomery C.A., Butel J.S., Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992, 356:215-221.
5. Doyle J.M., Gao J., Wang J., Yang M., Potts P.R. MAGE-RING protein complexes comprise a family of E3 ubiquitin ligases. Mol. Cell 2010, 39:963-974.
6. Feng L., Lin T., Uranishi H., Gu W., Xu Y. Functional analysis of the roles of posttranslational modifications at the p53 C terminus in regulating p53 stability and activity. Mol. Cell. Biol. 2005, 25:5389-5395.
7. Fukuzawa R., Holman S.K., Chow C.W., Savarirayan R., Reeve A.E., Robertson S.P. WTX mutations can occur both early and late in the pathogenesis of Wilms tumour. J. Med. Genet. 2010, 47:791-794.
8. Goodman R.H., Smolik S. CBP/p300 in cell growth, transformation, and development. Genes Dev. 2000, 14:1553-1577.
9. Grand R.J., Parkhill J., Szestak T., Rookes S.M., Roberts S., Gallimore P.H. Definition of a major p53 binding site on Ad2E1B58K protein and a possible nuclear localization signal on the Ad12E1B54K protein. Oncogene 1999, 18:955-965.
10. Grohmann A., Tanneberger K., Alzner A., Schneikert J., Behrens J. AMER1 regulates the distribution of the tumor suppressor APC between microtubules and the plasma membrane. J. Cell Sci. 2007, 120:3738-3747.
11. Gu W., Roeder R.G. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 1997, 90:595-606.
12. Harada J.N., Shevchenko A., Shevchenko A., Pallas D.C., Berk A.J. Analysis of the adenovirus E1B-55K-anchored proteome reveals its link to ubiquitination machinery. J. Virol. 2002, 76:9194-9206.
13. Ito A., Lai C.H., Zhao X., Saito S., Hamilton M.H., Appella E., Yao T.P. p300/CBP-mediated p53 acetylation is commonly induced by p53-activating agents and inhibited by MDM2. EMBO J. 2001, 20:1331-1340.
14. Jacks T., Remington L., Williams B.O., Schmitt E.M., Halachmi S., Bronson R.T., Weinberg R.A. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 1994, 4:1-7.
15. Janknecht R. The versatile functions of the transcriptional coactivators p300 and CBP and their roles in disease. Histol. Histopathol. 2002, 17:657-668.
16. Jenkins Z.A., van Kogelenberg M., Morgan T., Jeffs A., Fukuzawa R., Pearl E., Thaller C., Hing A.V., Porteous M.E., Garcia-Miñaur S., et al. Germline mutations in WTX cause a sclerosing skeletal dysplasia but do not predispose to tumorigenesis. Nat. Genet. 2009, 41:95-100.
17. Juan L.J., Shia W.J., Chen M.H., Yang W.M., Seto E., Lin Y.S., Wu C.W. Histone deacetylases specifically down-regulate p53-dependent gene activation. J. Biol. Chem. 2000, 275:20436-20443.
18. Kao C.C., Yew P.R., Berk A.J. Domains required for in vitro association between the cellular p53 and the adenovirus 2 E1B 55K proteins. Virology 1990, 179:806-814.
19. Kitagawa M., Lee S.H., McCormick F. Skp2 suppresses p53-dependent apoptosis by inhibiting p300. Mol. Cell 2008, 29:217-231.
20. Kobet E., Zeng X., Zhu Y., Keller D., Lu H. MDM2 inhibits p300-mediated p53 acetylation and activation by forming a ternary complex with the two proteins. Proc. Natl. Acad. Sci. USA 2000, 97:12547-12552.
21. Krummel K.A., Lee C.J., Toledo F., Wahl G.M. The C-terminal lysines fine-tune P53 stress responses in a mouse model but are not required for stability control or transactivation. Proc. Natl. Acad. Sci. USA 2005, 102:10188-10193.
22. Laptenko O., Prives C. Transcriptional regulation by p53: one protein, many possibilities. Cell Death Differ. 2006, 13:951-961.
23. Lee S.B., Haber D.A. Wilms tumor and the WT1 gene. Exp. Cell Res. 2001, 264:74-99.
24. Levine A.J. The common mechanisms of transformation by the small DNA tumor viruses: The inactivation of tumor suppressor gene products: p53. Virology 2009, 384:285-293.
25. Liu L., Scolnick D.M., Trievel R.C., Zhang H.B., Marmorstein R., Halazonetis T.D., Berger S.L. p53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage. Mol. Cell. Biol. 1999, 19:1202-1209.
26. Liu Y., Colosimo A.L., Yang X.J., Liao D. Adenovirus E1B 55-kilodalton oncoprotein inhibits p53 acetylation by PCAF. Mol. Cell. Biol. 2000, 20:5540-5553.
27. Liu Y., Shevchenko A., Shevchenko A., Berk A.J. Adenovirus exploits the cellular aggresome response to accelerate inactivation of the MRN complex. J. Virol. 2005, 79:14004-14016.
28. Luo J., Su F., Chen D., Shiloh A., Gu W. Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 2000, 408:377-381.
29. Luo J., Nikolaev A.Y., Imai S., Chen D., Su F., Shiloh A., Guarente L., Gu W. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 2001, 107:137-148.
30. Maheswaran S., Park S., Bernard A., Morris J.F., Rauscher F.J., Hill D.E., Haber D.A. Physical and functional interaction between WT1 and p53 proteins. Proc. Natl. Acad. Sci. USA 1993, 90:5100-5104.
31. Maheswaran S., Englert C., Lee S.B., Ezzel R.M., Settleman J., Haber D.A. E1B 55K sequesters WT1 along with p53 within a cytoplasmic body in adenovirus-transformed kidney cells. Oncogene 1998, 16:2041-2050.
32. Major M.B., Camp N.D., Berndt J.D., Yi X., Goldenberg S.J., Hubbert C., Biechele T.L., Gingras A.C., Zheng N., Maccoss M.J., et al. Wilms tumor suppressor WTX negatively regulates WNT/beta-catenin signaling. Science 2007, 316:1043-1046.
33. Moisan A., Rivera M.N., Lotinun S., Akhavanfard S., Coffman E.J., Cook E.B., Stoykova S., Mukherjee S., Schoonmaker J.A., Burger A., et al. The WTX tumor suppressor regulates mesenchymal progenitor cell fate specification. Dev. Cell 2011, 20:583-596.
34. Muller S., Dobner T. The adenovirus E1B-55K oncoprotein induces SUMO modification of p53. Cell Cycle 2008, 7:754-758.
35. Petrij F., Giles R.H., Dauwerse H.G., Saris J.J., Hennekam R.C., Masuno M., Tommerup N., van Ommen G.J., Goodman R.H., Peters D.J., et al. Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP. Nature 1995, 376:348-351.
36. Punga T., Akusjärvi G. The adenovirus-2 E1B-55K protein interacts with a mSin3A/histone deacetylase 1 complex. FEBS Lett. 2000, 476:248-252.
37. Querido E., Blanchette P., Yan Q., Kamura T., Morrison M., Boivin D., Kaelin W.G., Conaway R.C., Conaway J.W., Branton P.E. Degradation of p53 by adenovirus E4orf6 and E1B55K proteins occurs via a novel mechanism involving a Cullin-containing complex. Genes Dev. 2001, 15:3104-3117.
38. Reddy J.C., Licht J.D. The WT1 Wilms' tumor suppressor gene: how much do we really know?. Biochim. Biophys. Acta 1996, 1287:1-28.
39. Rivera M.N., Haber D.A. Wilms' tumour: connecting tumorigenesis and organ development in the kidney. Nat. Rev. Cancer 2005, 5:699-712.
40. Rivera M.N., Kim W.J., Wells J., Driscoll D.R., Brannigan B.W., Han M., Kim J.C., Feinberg A.P., Gerald W.L., Vargas S.O., et al. An X chromosome gene, WTX, is commonly inactivated in Wilms tumor. Science 2007, 315:642-645.
41. Rivera M.N., Kim W.J., Wells J., Stone A., Burger A., Coffman E.J., Zhang J., Haber D.A. The tumor suppressor WTX shuttles to the nucleus and modulates WT1 activity. Proc. Natl. Acad. Sci. USA 2009, 106:8338-8343.
42. Sakaguchi K., Herrera J.E., Saito S., Miki T., Bustin M., Vassilev A., Anderson C.W., Appella E. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev. 1998, 12:2831-2841.
43. Schedl A., Hastie N. Multiple roles for the Wilms' tumour suppressor gene, WT1 in genitourinary development. Mol. Cell. Endocrinol. 1998, 140:65-69.
44. Scolnick D.M., Chehab N.H., Stavridi E.S., Lien M.C., Caruso L., Moran E., Berger S.L., Halazonetis T.D. CREB-binding protein and p300/CBP-associated factor are transcriptional coactivators of the p53 tumor suppressor protein. Cancer Res. 1997, 57:3693-3696.
45. Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., Paulovich A., Pomeroy S.L., Golub T.R., Lander E.S., Mesirov J.P. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 2005, 102:15545-15550.
46. Sykes S.M., Mellert H.S., Holbert M.A., Li K., Marmorstein R., Lane W.S., McMahon S.B. Acetylation of the p53 DNA-binding domain regulates apoptosis induction. Mol. Cell 2006, 24:841-851.
47. Tang Y., Zhao W., Chen Y., Zhao Y., Gu W. Acetylation is indispensable for p53 activation. Cell 2008, 133:612-626.
48. Tanneberger K., Pfister A.S., Brauburger K., Schneikert J., Hadjihannas M.V., Kriz V., Schulte G., Bryja V., Behrens J. Amer1/WTX couples Wnt-induced formation of PtdIns(4,5)P2 to LRP6 phosphorylation. EMBO J. 2011, 30:1433-1443.
49. Vaziri H., Dessain S.K., Ng Eaton E., Imai S.I., Frye R.A., Pandita T.K., Guarente L., Weinberg R.A. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 2001, 107:149-159.
50. Vogelstein B., Lane D., Levine A.J. Surfing the p53 network. Nature 2000, 408:307-310.
51. Vousden K.H., Prives C. Blinded by the Light: The Growing Complexity of p53. Cell 2009, 137:413-431.
52. Wang W., Lee S.B., Palmer R., Ellisen L.W., Haber D.A. A functional interaction with CBP contributes to transcriptional activation by the Wilms tumor suppressor WT1. J. Biol. Chem. 2001, 276:16810-16816.
53. Wimmer P., Schreiner S., Everett R.D., Sirma H., Groitl P., Dobner T. SUMO modification of E1B-55K oncoprotein regulates isoform-specific binding to the tumour suppressor protein PML. Oncogene 2010, 29:5511-5522.
54. Yew P.R., Liu X., Berk A.J. Adenovirus E1B oncoprotein tethers a transcriptional repression domain to p53. Genes Dev. 1994, 8:190-202.
55. Zantema A., Fransen J.A., Davis-Olivier A., Ramaekers F.C., Vooijs G.P., DeLeys B., Van der Eb A.J. Localization of the E1B proteins of adenovirus 5 in transformed cells, as revealed by interaction with monoclonal antibodies. Virology 1985, 142:44-58.